Free Trial

LENZ Therapeutics (LENZ) Competitors

LENZ Therapeutics logo
$28.22 +0.06 (+0.21%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$27.31 -0.91 (-3.22%)
As of 08:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LENZ vs. MTSR, VKTX, AKRO, ALVO, CPRX, CRNX, SRRK, MRUS, MOR, and PTGX

Should you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include Metsera (MTSR), Viking Therapeutics (VKTX), Akero Therapeutics (AKRO), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Crinetics Pharmaceuticals (CRNX), Scholar Rock (SRRK), Merus (MRUS), MorphoSys (MOR), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

LENZ Therapeutics vs.

Metsera (NASDAQ:MTSR) and LENZ Therapeutics (NASDAQ:LENZ) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, community ranking, risk and valuation.

LENZ Therapeutics received 11 more outperform votes than Metsera when rated by MarketBeat users.

CompanyUnderperformOutperform
MetseraOutperform Votes
4
100.00%
Underperform Votes
No Votes
LENZ TherapeuticsOutperform Votes
15
100.00%
Underperform Votes
No Votes

Metsera presently has a consensus target price of $47.00, indicating a potential upside of 67.56%. LENZ Therapeutics has a consensus target price of $46.60, indicating a potential upside of 65.13%. Given Metsera's higher possible upside, equities analysts clearly believe Metsera is more favorable than LENZ Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Metsera
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
LENZ Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

54.3% of LENZ Therapeutics shares are held by institutional investors. 38.4% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MetseraN/AN/AN/AN/AN/A
LENZ TherapeuticsN/AN/A-$124.65M-$1.77-15.94

Metsera's return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MetseraN/A N/A N/A
LENZ Therapeutics N/A -58.48%-55.50%

In the previous week, LENZ Therapeutics had 3 more articles in the media than Metsera. MarketBeat recorded 3 mentions for LENZ Therapeutics and 0 mentions for Metsera. LENZ Therapeutics' average media sentiment score of 1.65 beat Metsera's score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Metsera Neutral
LENZ Therapeutics Very Positive

Summary

LENZ Therapeutics beats Metsera on 8 of the 11 factors compared between the two stocks.

Get LENZ Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LENZ vs. The Competition

MetricLENZ TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$794.28M$2.93B$5.33B$8.39B
Dividend YieldN/A1.63%5.21%4.10%
P/E Ratio-15.9431.1826.7719.70
Price / SalesN/A398.78393.27122.35
Price / CashN/A168.6838.2534.62
Price / Book1.283.236.774.50
Net Income-$124.65M-$72.35M$3.23B$248.22M
7 Day Performance5.26%2.49%0.43%-0.80%
1 Month Performance4.71%2.45%9.07%11.52%
1 Year Performance79.52%-24.98%18.57%8.99%

LENZ Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LENZ
LENZ Therapeutics
1.9263 of 5 stars
$28.22
+0.2%
$46.60
+65.1%
+53.3%$794.28MN/A-15.94110Gap Up
MTSR
Metsera
N/A$28.96
-1.9%
$47.00
+62.3%
N/A$3.10BN/A0.0081Gap Down
VKTX
Viking Therapeutics
4.4196 of 5 stars
$27.50
-3.3%
$87.15
+216.9%
-56.0%$3.09BN/A-27.5020Positive News
AKRO
Akero Therapeutics
3.8084 of 5 stars
$38.14
-1.9%
$82.33
+115.9%
+138.9%$3.04BN/A-10.1730
ALVO
Alvotech
1.7535 of 5 stars
$10.07
-3.7%
$18.00
+78.7%
-29.0%$3.04B$585.60M-5.444
CPRX
Catalyst Pharmaceuticals
4.6118 of 5 stars
$24.63
+1.1%
$32.29
+31.1%
+49.4%$3.00B$534.65M20.8780Positive News
CRNX
Crinetics Pharmaceuticals
3.5443 of 5 stars
$30.95
-0.9%
$73.00
+135.9%
-40.4%$2.90B$760,000.00-8.30210Positive News
SRRK
Scholar Rock
3.9788 of 5 stars
$30.16
-1.3%
$42.67
+41.5%
+160.1%$2.86B$33.19M-12.83140
MRUS
Merus
3.2305 of 5 stars
$41.36
-0.5%
$84.54
+104.4%
-4.1%$2.86B$54.73M-10.4737Positive News
Options Volume
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
PTGX
Protagonist Therapeutics
3.3858 of 5 stars
$45.57
+2.4%
$65.44
+43.6%
+44.8%$2.82B$207.80M17.13120Positive News

Related Companies and Tools


This page (NASDAQ:LENZ) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners